Researchers at QIMR Berghofer Medical Research Institute are developing an AI-enabled device to enhance the effectiveness of transcranial magnetic stimulation (TMS) therapy for major depressive disorder. The technology aims to analyse brain network-derived biomarkers to predict how individual patients will respond to TMS. This means treatment can be better targeted, improving outcomes for those most likely to benefit and reducing wait times for others who may need different support. With mental illness affecting millions of Australians each year, this innovation offers a more personalised and efficient approach to patient care.
This ground-breaking work has been supported by the National Imaging Facility, with MRI imaging conducted at the Herston Imaging Research Facility. Access to advanced imaging capabilities has played a vital role in identifying the brain biomarkers that underpin this technology.
Supporting NIF Partner
